Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:CNTX NYSE:CVM NASDAQ:IGMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.25+0.6%$0.24$0.15▼$13.00$19.65M0.036.14 million shs3.32 million shsCNTXContext Therapeutics$0.84-1.4%$0.75$0.49▼$2.59$76.45M1.89172,341 shs82,615 shsCVMCEL-SCI$10.43+12.0%$6.28$1.98▼$39.30$71.78M0.52373,970 shs514,864 shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro+0.57%-1.57%-17.72%+13.26%+24,509,900.00%CNTXContext Therapeutics-1.43%-5.94%+3.81%+43.34%-65.85%CVMCEL-SCI+12.03%+9.56%+21.56%+396.67%-67.96%IGMSIGM Biosciences0.00%0.00%+0.79%-0.78%-87.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/ACNTXContext Therapeutics3.5171 of 5 stars3.64.00.00.03.31.71.3CVMCEL-SCI0.4868 of 5 stars0.04.00.00.00.01.70.6IGMSIGM Biosciences4.5431 of 5 stars3.03.00.04.63.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,531.99% UpsideCNTXContext Therapeutics 3.17Buy$5.25525.00% UpsideCVMCEL-SCI 0.00N/AN/AN/AIGMSIGM Biosciences 1.90Reduce$5.50333.07% UpsideCurrent Analyst Ratings BreakdownLatest ABP, CNTX, CVM, and IGMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.008/7/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/26/2025CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K107.37N/AN/A($0.21) per share-1.17CNTXContext TherapeuticsN/AN/AN/AN/A$0.92 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AIGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-241.16%N/ACNTXContext Therapeutics-$26.73M-$0.36N/AN/AN/AN/A-38.80%-37.53%11/5/2025 (Estimated)CVMCEL-SCI-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/AIGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)Latest ABP, CNTX, CVM, and IGMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ABPAbproN/A-$0.04N/A-$0.05N/AN/A8/6/2025Q2 2025CNTXContext Therapeutics-$0.06-$0.09-$0.03-$0.09N/AN/A7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.150.15CNTXContext TherapeuticsN/A19.0919.09CVMCEL-SCI0.661.071.09IGMSIGM BiosciencesN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%CNTXContext Therapeutics14.03%CVMCEL-SCI12.08%IGMSIGM Biosciences42.79%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%CNTXContext Therapeutics2.80%CVMCEL-SCI9.93%IGMSIGM Biosciences57.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1580.17 million63.49 millionN/ACNTXContext Therapeutics789.70 million87.19 millionNot OptionableCVMCEL-SCI436.88 million64.67 millionOptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableABP, CNTX, CVM, and IGMS HeadlinesRecent News About These CompaniesWall Street Zen Upgrades IGM Biosciences (NASDAQ:IGMS) to HoldAugust 17, 2025 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by AnalystsAugust 15, 2025 | marketbeat.comIGM Biosciences (IGMS) Expected to Announce Earnings on WednesdayAugust 7, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Announces Earnings ResultsAugust 2, 2025 | marketbeat.comIGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass EstimatesJuly 31, 2025 | zacks.comIGM Biosciences, Inc. (NASDAQ:IGMS) CFO Sells $11,101.07 in StockJuly 26, 2025 | insidertrades.comIGM Biosciences Enters Definitive Merger Agreement with Concentra Biosciences for Acquisition - NasdaqJuly 3, 2025 | nasdaq.comIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 3, 2025 | seekingalpha.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders - MorningstarJuly 3, 2025 | morningstar.comMIGM Biosciences to be acquired by ConcentraJuly 2, 2025 | thepharmaletter.comTConcentra acquires IGM Biosciences, continuing M&A streak with struggling biotechsJuly 2, 2025 | fiercebiotech.comFIGM Biosciences Shares Surge on Takeover Agreement with ConcentraJuly 2, 2025 | msn.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to ShareholdersJuly 1, 2025 | businesswire.comIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value RightJuly 1, 2025 | globenewswire.comIGM Biosciences Terminates Headquarters Lease AgreementMay 29, 2025 | tipranks.comIGM Biosciences earnings missed by $0.51, revenue fell short of estimatesMay 24, 2025 | investing.comIGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comIGM Biosciences ends agreement with SanofiMay 10, 2025 | investing.comIGM Biosciences says it is dropping development of imvotamabMay 10, 2025 | thepharmaletter.comTWhy IGM Biosciences, Inc.’s (IGMS) Stock Is Down 6.85%April 24, 2025 | aaii.comAWhy IGM Biosciences, Inc.’s (IGMS) Stock Is Down 5.91%April 17, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeABP, CNTX, CVM, and IGMS Company DescriptionsAbpro NASDAQ:ABP$0.25 +0.00 (+0.57%) As of 08/29/2025 03:59 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Context Therapeutics NASDAQ:CNTX$0.84 -0.01 (-1.20%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.CEL-SCI NYSE:CVM$10.43 +1.12 (+12.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.46 +0.03 (+0.25%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.IGM Biosciences NASDAQ:IGMS$1.27 0.00 (0.00%) As of 08/14/2025IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
